{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:38:03Z","timestamp":1782949083061,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Durvalumab (Imfinzi<jats:sup>\u00ae<\/jats:sup>), a therapeutic human monoclonal antibody which binds to and blocks the activity of the immunosuppressive programmed death-ligand 1 (PD-L1) protein, is approved in the USA, EU, Japan and other countries in combination with gemcitabine and cisplatin for adults with advanced biliary tract cancer. In the pivotal phase 3 TOPAZ-1 trial, durvalumab plus gemcitabine and cisplatin significantly prolonged overall survival and progression-free survival compared with placebo plus gemcitabine and cisplatin in adults with advanced biliary tract cancer. Benefit from durvalumab was seen irrespective of primary tumour location, disease status at diagnosis (unresectable or recurrent), or initial levels of PD-L1 expression. The tolerability of durvalumab plus gemcitabine and cisplatin was manageable. Overall, the addition of durvalumab to gemcitabine and cisplatin is a valuable new treatment option for adults with advanced biliary tract cancer.<\/jats:p>","DOI":"10.1007\/s11523-023-01007-y","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T10:01:59Z","timestamp":1699524119000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Durvalumab: A Review in Advanced Biliary Tract Cancer"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"10272","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet"},{"issue":"2","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol"},{"key":"1007_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2022.11.006","volume":"179","author":"GS Roth","year":"2023","unstructured":"Roth GS, Neuzillet C, Sarabi M, et al. Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine? Eur J Cancer. 2023;179:1\u201314.","journal-title":"Eur J Cancer"},{"issue":"14","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med"},{"issue":"4","key":"1007_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374.","journal-title":"Br J Cancer"},{"issue":"1","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C, et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017;80(1):209\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1007_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3892\/ol.2017.6105","volume":"14","author":"K Ma","year":"2017","unstructured":"Ma K, Wei X, Dong D, et al. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14(1):250\u20136.","journal-title":"Oncol Lett"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2019.04.017","volume":"454","author":"Q Luo","year":"2019","unstructured":"Luo Q, Zhang L, Luo C, et al. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 2019;454:191\u2013203.","journal-title":"Cancer Lett"},{"issue":"9","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res. 2015;3(9):1052\u201362.","journal-title":"Cancer Immunol Res"},{"key":"1007_CR10","unstructured":"AstraZeneca Pharmaceuticals LP. IMFINZI\u00ae (durvalumab) injection, for intravenous use: US prescribing information. 2022. https:\/\/www.fda.gov\/. Accessed 11 Oct 2023."},{"key":"1007_CR11","unstructured":"AstraZeneca AB. IMFINZI (durvalumab): EU summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/. Accessed 11 Oct 2023."},{"key":"1007_CR12","unstructured":"AstraZeneca Co. Ltd. Imfinzi\u00ae intravenous infusion 120mg \/ Imfinzi\u00ae intravenous Infusion 500mg: Japanese prescribing information. 2022. https:\/\/www.pmda.go.jp\/. Accessed 11 Oct 2023."},{"issue":"9","key":"1007_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol. 2017;3(9): e172411.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"DY Oh","year":"2022","unstructured":"Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 2022;7(6):522\u201332.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1007_CR15","doi-asserted-by":"crossref","unstructured":"Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase 1 study of MEDI4736, an anti\u2013PD-L1 antibody, in patients with advanced solid tumors [abstract no. 3001]. J Clin Oncol. 2014;32(Suppl. 15):3001.","DOI":"10.1200\/jco.2014.32.15_suppl.3001"},{"issue":"4","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/cpt.982","volume":"103","author":"PG Baverel","year":"2018","unstructured":"Baverel PG, Dubois VFS, Jin CY, et al. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther. 2018;103(4):631\u201342.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1007_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1(8):1\u201311.","journal-title":"NEJM Evid."},{"key":"1007_CR18","doi-asserted-by":"crossref","unstructured":"Valle JW, Qin S, Antonuzzo L, et al. Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC) [abstract no. 68O plus presentation]. Ann Oncol. 2022;33(Suppl. 9):S1457.","DOI":"10.1016\/j.annonc.2022.10.104"},{"key":"1007_CR19","doi-asserted-by":"crossref","unstructured":"Oh DY, He AR, Qin S, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in patients (pts) with advanced biliary tract cancer (BTC) [abstract no. 56P plus poster]. Ann Oncol. 2022;33(Suppl. 7):S565\u2013S6.","DOI":"10.1016\/j.annonc.2022.07.084"},{"key":"1007_CR20","doi-asserted-by":"crossref","unstructured":"Burris HA, III, Okusaka T, Vogel A, et al. Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer [abstract no. 4070 plus poster]. J Clin Oncol. 2022;40(Suppl. 16):4070.","DOI":"10.1200\/JCO.2022.40.16_suppl.4070"},{"issue":"8","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803\u201312.","journal-title":"Liver Int"},{"issue":"10212","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339.","journal-title":"Lancet"},{"key":"1007_CR23","doi-asserted-by":"crossref","unstructured":"Antonuzzo L, Takahashi H, Park JO, et al. Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC) [abstract no. 57P plus poster]. Ann Oncol. 2022;33(Suppl. 7):S566-S7.","DOI":"10.1016\/j.annonc.2022.07.085"},{"key":"1007_CR24","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: biliary tract cancers (v2.2023). 2023. www.nccn.org\/. Accessed 11 Oct 2023."}],"updated-by":[{"DOI":"10.1007\/s11523-023-01021-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000}}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-01007-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-01007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:30:29Z","timestamp":1701261029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-01007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-01007-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11523-023-01021-0","asserted-by":"object"}]},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"10 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11523-023-01021-0","URL":"https:\/\/doi.org\/10.1007\/s11523-023-01021-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S. Fung and Y. Y. Syed are salaried employee of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}